Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
DYN

DYN - Dyne Therapeutics Inc Stock Price, Fair Value and News

$18.19+0.24 (+1.34%)
Market Closed as of 12 Jun 2026, 04:00 pm ET

20/100

DYN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

20/100

DYN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

DYN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

DYN Price Action

Last 7 days

6.8%

Last 30 days

-1.4%

Last 90 days

1.5%

Trailing 12 Months

25.8%

DYN RSI Chart

DYN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

DYN Valuation

Market Cap

3.0B

Price/Earnings (Trailing)

-6.65

Price/Sales (Trailing)

95.35

Price/Free Cashflow

-6.78

DYN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

DYN Fundamentals

DYN Revenue

Revenue (TTM)

31.5M

Rev. Growth (Yr)

23.34%

Rev. Growth (Qtr)

14.36%

DYN Earnings

Earnings (TTM)

-451.7M

Earnings Growth (Yr)

-4.76%

Earnings Growth (Qtr)

-7.95%

DYN Profitability

Return on Equity

-52.22%

Return on Assets

-41.83%

Free Cashflow Yield

-14.76%

DYN Investor Care

Shares Dilution (1Y)

45.38%

Diluted EPS (TTM)

-3.17

DYN Alerts

  • 1 major insider buys and 1 major insider sales recently.
  • Losses in recent quarter

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202631.5M000
202531.0M30.6M29.8M29.9M
20249.1M14.0M21.1M26.9M
20234.2M5.9M7.2M7.6M
2022806.0K1.0M1.8M2.9M
2021198.0K408.0K592.0K742.0K
2020231.5K173.0K114.5K56.0K
2019000290.0K
20180000
Get all data in R, Python etc through our Historical Stock Data APIs

About Dyne Therapeutics Inc

DYN
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
 CEO
 WEBSITEdyne-tx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES134

Dyne Therapeutics Inc Frequently Asked Questions

DYN is the stock ticker symbol of Dyne Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Jun 12 2026, market cap of Dyne Therapeutics Inc is 3.01 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Jun 12 2026, DYN's PE ratio (Price to Earnings) is -6.65 and Price to Sales (PS) ratio is 95.35. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DYN PE ratio will change depending on the future growth rate expectations of investors.